Pharma-Bio Serv (PBSV) Cash & Equivalents (2010 - 2026)

Pharma-Bio Serv has reported Cash & Equivalents for 17 years, with the latest figure at $5.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 21.12% year-over-year to $5.8 million; the trailing twelve-month figure through Jan 2026 stood at $5.8 million (down 21.12% YoY), and the FY2025 full-year result was $3.4 million, down 50.07% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $5.8 million, up from $3.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $15.4 million in Q1 2022, with the low at $2.1 million in Q2 2025.
• Historically, Cash & Equivalents has averaged $7.7 million across 5 years, with a median of $6.8 million in 2024.
• Annual changes were most pronounced in 2023 — Cash & Equivalents tumbled 79.85% — and 2024, when it surged 127.22%.
• Pharma-Bio Serv's Cash & Equivalents stood at $14.5 million in 2022, then dropped by 27.77% to $10.4 million in 2023, then sank by 35.22% to $6.8 million in 2024, then sank by 50.07% to $3.4 million in 2025, then jumped by 70.56% to $5.8 million in 2026.
• The last three Cash & Equivalents figures came in at $5.8 million (Q1 2026), $3.4 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.